Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
| ▸ | PDE1A | P54750 | 5/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837350 | 0.85 | AADAT (0.43) | AADATPDE1APDE1BPDE1CCMA1 | |
| SCHEMBL365921 | 0.83 | AADAT (0.39) | AADATCHRM5PDE1APDE1BPDE1C | |
| SCHEMBL366177 | 0.82 | AADAT (0.41) | AADATPDE1APDE1BPDE1CCMA1 | |
| SCHEMBL15182504 | 0.77 | AADAT (0.46) | AADATCMA1HCRTR1HCRTR2GAA | |
| SCHEMBL6837296 | 0.75 | AADAT (0.43) | AADATCMA1HCRTR1HCRTR2GAA | |
| SCHEMBL366615 | 0.75 | AADAT (0.42) | AADATCMA1SMN1; SMN2GAA | |
| SCHEMBL366179 | 0.73 | AADAT (0.41) | AADATPDE1APDE1BPDE1CCMA1 | |
| SCHEMBL365074 | 0.73 | AADAT (0.43) | AADATCMA1HCRTR1HCRTR2GAA | |
| SCHEMBL6837301 | 0.73 | ALDH1A1 (0.48) | AADATCMA1SMN1; SMN2GAA | |
| SCHEMBL365659 | 0.73 | ALDH1A1 (0.48) | AADATCMA1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252944-A1 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. | 2013-09-26 | — | — | US | disclosed |
| EP-2593277-A2 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009000-A2 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252944-A1 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | AADAT 837/4885CHRM5 165/4885PDE1A 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.